201478-72-0

Basic information

• Product Name: 3-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: N-CBZ-3-FORMYLPIPERIDINE;N-CBZ-3-PIPERIDINYLCARBOXALDEHYDE;BENZYL 3-FORMYLPIPERIDINE-1-CARBOXYLATE;1-CBZ-PIPERIDINE-3-ALDEHYDE;3-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;Benzyl 3-formylpiperidine-1-carboxylate 97%;1-Cbz-3-Piperidinecarboxaldehyde;N-CBZ-3-piperidinecarboxaldehyde
• CAS NO: 201478-72-0
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.29
• Mol File: 201478-72-0.mol

Chemical Properties

• Boiling Point: 384.503 °C at 760 mmHg
• Flash Point: 186.341 °C
• Appearance: /
• Density: 1.222 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.594
• PKA: -2.34±0.40(Predicted)
• CAS DataBase Reference: 3-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(201478-72-0)
• EPA Substance Registry System: 3-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(201478-72-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 201478-72-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
3-Formyl-piperidine-1-carboxylic Acid Benzyl Ester is used as a chemical intermediate for the synthesis of more complex chemicals. Its reactive carbonyl group allows for various reactions and transformations, making it a valuable component in the development of new compounds.
Used in Pharmaceutical Industry:
3-Formyl-piperidine-1-carboxylic Acid Benzyl Ester is used as a building block in the synthesis of pharmaceutical compounds. Its unique molecular structure, including the piperidine ring, benzyl ester group, and formyl group, contributes to the creation of novel drug molecules with potential therapeutic applications.
Used in Chemical Industry:
3-Formyl-piperidine-1-carboxylic Acid Benzyl Ester is used as a key component in the production of specialty chemicals. Its versatility in undergoing various chemical reactions enables the creation of a wide range of chemical products for different applications, such as materials science, coatings, and adhesives.

InChI:InChI=1/C14H17NO3/c16-10-13-7-4-8-15(9-13)14(17)18-11-12-5-2-1-3-6-12/h1-3,5-6,10,13H,4,7-9,11H2

Upstream product

• 39945-51-2 benzyl 3-(hydroxymethyl)-1-piperidinecarboxylate 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 87413-09-0 Dess-Martin periodane 
• 501-53-1 benzyl chloroformate 
• 71962-74-8 Ethyl nipecotate 
• 310454-53-6 3-ethyl 1-(phenylmethyl) 1,3-piperidinedicarboxylate 
• 405239-72-7 benzyl 3-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate 
• 42116-21-2 2-benzyloxycarbonylsulfanyl-4,6-dimethyl-pyrimidine 

Downstream Products

• 712353-22-5 C₂₆H₂₈N₂O₄S 
• 405239-74-9 tert-butyl 2-amino-4-{1-[(benzyloxy)carbonyl]-3-piperidinyl}-6-{2-[(4-methoxybenzyl)oxy]phenyl}nicotinate 
• 1245212-11-6 3,3-(2,3-dihydro-1H-indol-3-yl)-piperidine-1-carboxylic acid benzyl ester 
• 876148-23-1 1-benzyloxycarbonyl-3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piperidine 
• 1341126-88-2 benzyl 3-{[(2-aminoethyl)amino]methyl}piperidine-1-carboxylate 
• 1341126-87-1 benzyl 3-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)methyl]piperidine-1-carboxylate 
• 1341126-85-9 1-benzyl-3-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)methyl]piperidine 
• 784080-46-2 3-(1H-imidazol-5-yl)piperidine 
• 1352654-77-3 benzyl 3-(1H-imidazol-2-yl)piperidine-1-carboxylate 
• 1352654-87-5 benzyl 3-(1H-imidazol-5-yl)piperidine-1-carboxylate 

Relevant articles and documents

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

Potent inhibition of Norwalk virus by cyclic sulfamide derivatives

A new class of compounds that exhibit anti-norovirus activity in a cell-based system and embody in their structure a cyclosulfamide scaffold has been identified. The structure of the initial hit (compound 2a, ED50 4 μM, TD50 50 μM) has been prospected by exploiting multiple points of diversity and generating appropriate structure-activity relationships.

Disubstituted pyrimidines as Lck inhibitors

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

Pyridine derivatives

Pyridine compounds of general formula: wherein —R1represents in which R11is hydrogen, C1-6alkyl, halogen, hydroxy, C1-12alkoxy, nitro, amino, C1-6alkylsulfonylamino, C1-6alkoxycarbonyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkanoylamino, phenyl C1-6alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2represents hydrogen or halogen; R3represents hydrogen, —CR31R32R33, or —NR34R35; R4is hydrogen, carbamoyl, CN, carboxyl, etc.; R5is amino, C1-6alkylamino, di C1-6alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Src kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

Methods for the stereoselective synthesis of substituted piperidines

One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will

A novel class of potent γ-aminobutyric acid aminotransferase inhibitor, 3-(hydroxyamino)propylamine and analogues

Hydroxyamino analogues of γ-aminobutyric acid (GABA) were synthesized and evaluated for inhibitory activity toward γ-aminobutyric acid aminotransferase (GABA-T). The title compound, 3-(hydroxyamino)propylamine (HPA), showed a potent inhibitory activity. The inhibition is competitive with respect to GABA and the K(i) value of GABA-T for HPA is 0.4 mmol. The activity of inhibition is comparable to those of aminoxyacetic acid and valproic acid. 3-(Hydroxyaminomethyl)piperidine (3HMP), a cyclic analogue of HPA, also showed a patent inhibitory activity, whereas 3-(methoxyamino)propylamine (OMe-HPA), 3-(N-hydroxy-N-methylamino)propylamine (NMe-HPA) and 4-(hydroxyamino)piperidine (4HP) showed weak activity.